SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001072613-16-000556
Filing Date
2016-02-09
Accepted
2016-02-09 14:24:53
Documents
1
Group Members
CLARUS VENTURES I LLCCLARUS VENTURES I MANAGEMENT L.P.DENNIS HENNERKURT WHEELERMICHAEL STEINMETZNICHOLAS GALAKATOSNICHOLAS SIMONROBERT LIPTAK

Document Format Files

Seq Description Document Type Size
1 OXFORD IMMUNOTEC GLOBAL PLC - AMEND #1 clarus-oxfordsch13g_17901.htm SC 13G/A 301200
  Complete submission text file 0001072613-16-000556.txt   303028
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences I, L.P. (Filed by) CIK: 0001431445 (see all company filings)

IRS No.: 203855540 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 94C INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Business Address 94C INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ 44 01235 442780
Oxford Immunotec Global PLC (Subject) CIK: 0001586049 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-87926 | Film No.: 161398787
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences